CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

BACKGROUND: Neurodegeneration plays a major role in determining disability in multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression. OBJECTIVES: To assess whether cerebrospinal fluid (CSF) tau and \u3b2-amyloid (A\u3b2) levels were altered in newly diagnosed MS patients and correlated with disability. Moreover, we investigated whether these CSF biomarkers associate with macroscopic brain tissue damage measures. METHODS: CSF A\u3b2 and tau levels were determined by enzyme-linked immunosorbent assay in CSF samples from 48 newly diagnosed MS patients, followed-up clinically for 3\u2009years by recording their Expanded Disability Status Scale score at 6-month intervals, and 45 controls. All patients underwent magnetic resonance imaging at baseline and at the end of follow-up to quantify their lesion load (LL). RESULTS: CSF A\u3b2 levels were significantly reduced in patients compared to controls ( p\u2009<\u20090.001). Lower CSF A\u3b2 levels at baseline were a disability predictor at 3-year follow-up ( p\u2009=\u20090.009). CSF tau levels correlated with T2- and T1-LL ( p\u2009<\u20090.001). CONCLUSION: CSF A\u3b2 reduction is a promising biomarker of neurodegeneration and may predict patients' clinical outcome. Therefore, CSF A\u3b2 should be considered as a potential biomarker of prognostic value